Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

Hemispherx BioPharma, Inc (Public, AMEX:HEB)

13.337 Posts
Pagina: «« 1 ... 660 661 662 663 664 ... 667 »» | Laatste | Omlaag ↓
  3. [verwijderd] 30 december 2009 21:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    sjef 01 schreef:

    Wederom vanaf 15.30 een ordertje op 0,58$ weggezet, tot op heden nog niet binnen..Zo kom ik nooit aan mijn 20k...
    leg dan .5811 in ofzo
  4. [verwijderd] 31 december 2009 14:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Demenkovets schreef:

    [quote=sjef 01]
    Mag ik vragen waarom je ze niet gewoon houdt, met onze beider info is traden ff geen optie...

    Vanuit welke gedachte wil jij ze HEBben..?
    [/quote]

    Omdat ik de US aandelen bij de Rabo weg wil hebben en over wil zetten naar Binck. Probeer ik op deze manier te doen. Met een beetje geluk blijf je zo redelijk uit de kosten (over laten boeken is schrikbarend duur heb ik gezien).
    betaald binck hoor !!!
  5. Demenkovets 1 januari 2010 16:43

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    quote:

    ALTIJD FOUT schreef:

    [quote=Demenkovets]
    [quote=sjef 01]
    Mag ik vragen waarom je ze niet gewoon houdt, met onze beider info is traden ff geen optie...

    Vanuit welke gedachte wil jij ze HEBben..?
    [/quote]

    Omdat ik de US aandelen bij de Rabo weg wil hebben en over wil zetten naar Binck. Probeer ik op deze manier te doen. Met een beetje geluk blijf je zo redelijk uit de kosten (over laten boeken is schrikbarend duur heb ik gezien).
    [/quote]

    betaald binck hoor !!!

    Nee hoor, max 25 euro per fondsregel wordt door Binck vergoed (tot een max van 500 in totaal). Rabo vraagt 75 per regel aan kosten, dus 50 euro voor eigen rekening. Heb het uitgezocht en nagevraagd.

    Met een fondsregel of 10 gaat me dat toch iets teveel in de kosten lopen.
  8. [verwijderd] 2 januari 2010 11:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    welshterrier schreef:

    je kunt ze toch gewoon bij Rabo verkopen en bij Binck aankopen kost dan toch niet zoveel, alleen extra transactiekosten 2x
    gewoon 2 rekeningen aanhouden , en iedere keer als je wat verkoopt bij de rabo !!
    geld overboeken naar binck !!

    laat ze niet genieten van die kosten die ze in rek. willen brengen !!
    ps , abn overzetten 4 regels ( waaronder die claims fortis ) kostenn mij maar 87 totaal !!

  10. [verwijderd] 6 januari 2010 20:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Demenkovets schreef:

    Komt weer leven in, Real-Time: 0.65 Up 0.08 (14.02%) 2:46PM ET

    Flink volume laatste uur.
    Parameters extended in lawsuit against Hemispherx
    by John George Staff Writer

    * Print
    * Email
    * RSS Feed
    * Share
    *
    Comments

    Send this story to a friend
    Email address of friend (insert comma between multiple addresses): Your email address: Add a brief note:

    Enter words from the security image above:

    Get new image | Image verificationAudio verification | reCAPTCHA™

    Berger & Montague on Tuesday changed its class-action suit against Hemispherx Biopharma to expand its proposed class period to purchasers of the Philadelphia biotechnology company stock between Feb. 18, 2009, and Dec. 1, 2009.

    An earlier version of the lawsuit the Philadelphia law firm filed against Biopharma had a class period that ended Oct. 30, 2009. The litigation was filed in the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia.

    The complaint alleges that Hemispherx and its principal officer and director violated the federal securities laws by “making a series of false statements” about postponements of action on Hemispherx's New Drug Application for Ampligen with the Food and Drug Administration.

    Hemispherx, which has spent more than three decades developing Ampligen, is seeking approval for the new drug candidate as a treatment for chronic fatigue syndrome.

    The complaint alleges that Hemispherx portrayed the postponements in the FDA’s decision on its new drug application as caused by matters such as FDA staffing issues, while concealing that the delays were because of the company's failure to submit additional reports requested by the FDA and that questions had been raised by the agency about the adequacy of data submitted to demonstrate the drug's efficacy.

    When Hemispherx “belatedly” disclosed this information on Nov. 2, 2009, the complaint states, the price of Hemispherx stock dropped 22 percent from $1.45 per share to $1.13 per share on Nov. 3, 2009.

    On Dec. 1, 2009, after the market closed, Hemispherx announced that the FDA had denied the Ampligen’s new drug application.

    Hemispherx officials have since stated they are continuing to work with the FDA to resolve all the issues raised by the agency about Ampligen. Company representatives were not available Tuesday morning to comment on the class-action lawsuit.

    Categories: Health Care

    Companies: Berger & Montague, Hemispherx Biopharma
    Next Post > < Previous Post

    Reader Comments
    (0) Comments
    You must be logged in to add a comment. Please Login or Register.
  12. Demenkovets 28 januari 2010 20:09

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    10% erbij op dit nieuws:

    Stanford University Publishes New Data on Immuno-potential of Hemispherx's Ampligen(R)
    May Enhance Bioactivity of Cancer Immunotherapies

    Press Release Source: Hemispherx Biopharma, Inc. On Thursday January 28, 2010, 1:36 pm

    PHILADELPHIA, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced the publication of a peer-reviewed article providing study data on Ampligen® [rintatolimod; poly(I)·poly(C12,U)] , an experimental therapeutic, in the current issue of the American Journal of Obstetrics and Gynecology (Epub ahead of print Jan 15, 2010 vol 202). The report, whose lead author is Dr. Jonathan S. Berek, Professor and Chair, Obstetrics and Gynecology, Stanford University School of Medicine, and colleagues, further details results presented at the Pacific Coast Oncology Gynecology Society Meeting, La Jolla, California, on October 1, 2009. Entitled “Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy,” the article discusses the value of stimulating a periodic “danger signal” with a TLR3 agonist such as poly(I)·poly(C12,U) as part of immunotherapeutic cancer treatment regimens, and suggests such regimens may have broad potential application to boost the effects of many immunotherapies of cancer.

    The authors concluded that “poly(I)·poly(C12,U) shows promise as a potential agent for selective enhancement of effect with currently available and future cancer immunotherapies.” The authors also provided the following experimental observations in this report: “Dendritic cells are matured and T-cell stimulation is enhanced in the presence of poly(I)·poly(C12,U) . In addition, poly(I)·poly(C12,U) induced the release of proinflammatory chemokines and cytokines. Prostate-specific antigen-specific T-cell and antibody responses were enhanced significantly in a BALB/c prostate-specific antigen transgenic mouse model. Finally, rituximab [Rituxan®]-mediated antibody-dependent cellular cytotoxicity against tumor targets was improved significantly by the addition of poly(I)·poly(C12,U) .”

    According to the authors, “immunotherapy of cancer holds the promise of disease-specific intervention without the toxicity that is associated with traditional therapeutic modalities."

    The reported study was supported by an Ovarian Cancer Research Fund COGI Grant, Advanced Immune Therapeutics, Hemispherx Biopharma, and grants from the National Institute of Health (Grants CA 33399, CA 34233), the Ruth Kirschstein Award (Grant 5 T32 AI07290, and the Ruth L. Kirschstein Award (Grant F32 DKO78416).

    Ampligen® (poly(I)·poly(C12,U)), an experimental immunotherapeutic, is also being studied as an influenza vaccine enhancer (Japanese National Institute of Infectious Diseases) and as potential monotherapy for chronic fatigue syndrome (CFS).
  14. Demenkovets 2 februari 2010 16:10

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    quote:

    h980577. schreef:

    Wat is hier opeens aan de hand? + 20%...
    Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response

    Linkje werkt nog niet..
  15. Demenkovets 2 februari 2010 16:11

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    Hier dan:

    PHILADELPHIA, Feb 2, 2010 (GlobeNewswire via COMTEX) --

    Hemispherx Biopharma, Inc. (NYSE Amex: HEB | Quote | Chart | News | PowerRating) (the "Company"), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration ("FDA") Seattle District Office ("DO") related to the latest response to the Prior Approval Inspection submitted on Dec.11, 2009, and noted in Hemispherx' press release on Dec.16, 2009. The DO has accepted that certain manufacturing issues noted in the pre-approval inspection at the facility have been fully addressed and has made a recommendation for manufacturing approval with the Company's subcontractor listed as a manufacturing site to the FDA Office of Compliance in Washington, DC. The referenced response on Ampligen(R) (Poly I: Poly C12U), an experimental therapeutic being developed for potential treatment of Chronic Fatigue Syndrome ("CFS"), is the combined work-product of the staffs at Hemispherx and its subcontractor. These favorably resolved manufacturing issues are the same ones sited in the Complete Response Letter from the FDA described in Hemispherx' December 1, 2009 press release. The DO recommendations are not binding on the FDA and pertain only to the specific manufacturing issues cited in the Ampligen(R) manufacturing response.

    www.tradingmarkets.com/news/press-rel...
  18. h980577. 2 februari 2010 16:33

    • h980577.

      Lid sinds: 23 mrt 2003

      Laatste bezoek: 02 feb 2025

    • Aanbevelingen

      Ontvangen: 141

      Gegeven: 69

    •    Aantal posts: 2.593

    zo te lezen zegt dit nog niks over FDA goedkeuring, dus hoewel een mooie aanzet....laten we dan ook vast een mooie aanzet met de koers doen, zeg naar USD 1,50 ;)

  19. [verwijderd] 8 februari 2010 15:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    NEWS:

    New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect of Ampligen(R), an Experimental Therapeutic

    Independent University Researchers Find Ampligen(R) "Fully Protective" in Study
    February 08, 2010: 08:45 AM ET

    PHILADELPHIA, Feb. 8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") reported a recent study, published in the December 20th issue of Virology (2009) by a consortium of researchers at Utah State University and the University of North Carolina, on a newly developed animal model of severe acute respiratory disease syndrome (SARS) which, according to the authors, " ... largely mimicked human disease". SARS emerged in 2002 in the Guangdong province of Southern China as a new infectious respiratory disease characterized by influenza-like symptoms with a very high mortality rate. The researchers characterized and adapted a new strain of the SARS virus (SARS-CoV) to mice that was 100% lethal and was associated with the overproduction of cytokines and severe lung pathology (Day CW, et al. Virology, 395:210-222, 2009).

    Multiple agents with purported antiviral activity were evaluated for activity in this unique mouse model of the human disease, including Ampligen® (Poly I : Poly C12U), ribavirin (a commercially available antiviral with multiple modes of action for certain respiratory diseases) and other experimental agents. The researchers found that, uniquely among the agents tested, Ampligen®, an experimental therapeutic, " ... protected against death and gross damage to the lungs in the presence of lethal SARS-CoV" and was associated with a reduction in IL-6 concentration in which high levels of the cytokine correlated with the mortality of SARS-CoV infection. Mortality was high, under the conditions tested, for all the other antiviral agents examined, including ribavirin, that have previously been used extensively in humans with SARS without definitive evidence of efficacy (Stockman LJ, et al. PLoS Med 3 (9),e 343).

    To date, there are no approved agents for treating SARS. Animal experiments do not necessarily predict safety or efficacy in man. Encouraged by these results, Hemispherx is now in discussions with Chinese clinical research organizations to institute clinical antiviral programs in China.

    money.cnn.com/news/newsfeeds/articles...
  20. [verwijderd] 8 februari 2010 15:06

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    En gelijk de reactie:

    HEMISPHERX BIOPHARMA INC( HEB :AMEX)
    *Real Time Stock QuoteData is delayed|Source: NASDAQ Real-time Last Sale
    Extended Hours 0.74
    Last Trade 0.06 (+8.82%)

    Pre-Market Change
    * 24,400
    Volume 09:02:18 AM EST
13.337 Posts
Pagina: «« 1 ... 660 661 662 663 664 ... 667 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 6.997
AB InBev 2 5.479
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.125
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.450
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.623
Aedifica 3 900
Aegon 3.258 322.602
AFC Ajax 537 7.084
Affimed NV 2 6.287
ageas 5.844 109.883
Agfa-Gevaert 14 2.046
Ahold 3.538 74.287
Air France - KLM 1.025 34.973
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.020
Alfen 16 24.234
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 403
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.806
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.834 242.589
AMG 971 133.002
AMS 3 73
Amsterdam Commodities 305 6.685
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 481
Antonov 22.632 153.605
Aperam 92 14.886
Apollo Alternative Assets 1 17
Apple 5 375
Arcadis 252 8.731
Arcelor Mittal 2.033 320.447
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.282
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.061
ASML 1.766 105.380
ASR Nederland 21 4.450
ATAI Life Sciences 1 7
Atenor Group 1 466
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.581
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.383

Macro & Bedrijfsagenda

  1. 03 februari

    1. Beurs Shanghai gesloten (Chinees nieuwjaar)
    2. Inkoopmanagersindex industrie januari def. (Jap)
    3. Omzet detailhandel december (NL)
    4. Inflatie januari vlpg. (NL)
    5. Inkoopmanagersindex industrie januari (NL)
    6. Inkoopmanagersindex industrie januari def. (Spa)
    7. Inkoopmanagersindex industrie januari def. (Ita)
    8. Inkoopmanagersindex industrie januari def. (Fra)
    9. Inkoopmanagersindex industrie januari def. (Dld)
    10. Inkoopmanagersindex industrie januari def. (eur)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda